GENERICS AND BIOSIMILARS. HOW TO MAKE THE AVAILABLE ONES EVEN MORE ACCESSIBLE
Studio, Library
Panellists:
Sergey Glagolev, Deputy Minister of Health of the Russian Federation
Timofey Nizhegorodtsev, Deputy Head, Federal Antimonopoly Service of the Russian Federation
Alexander Plakida, Executive Director of the Effective Healthcare Interactive Platform
Today, it is difficult to identify the best or universal model for drug provision among the many existing in the world. The model is influenced by a large number of factors, and the dynamics of change in healthcare are such that all states are in search of a drug provision system with an optimal balance between the interests of the state, manufacturers, healthcare professionals and patients. The discussion will include the results of the analysis of the world's best regulatory practices of countries and allied unions and discussion of the ways to improve the system in the Russian Federation.
Discussion points: • Is there a concept of a global leader in generic and biosimilar availability? • The best is the enemy of the good: key criteria for optimal availability of generics and biosimilars. • Barriers to circulation and ways to overcome them. • Public procurement: how to maintain and develop a competitive environment?
